Is J&J Ottava FDA cleared?

No. Per FDA records + Agent A foundational ingest, Ottava has NOT yet received FDA clearance. The verified state is De Novo submission January 2026; FDA records list Ottava as "not authorized to be marketed." The De Novo pathway is for novel medical devices lacking a substantially-equivalent predicate; clearance is not automatic + timeline varies materially. Trade-press coverage framing January 2026 De Novo submission as imminent clearance is editorially imprecise; the verified gating event is FDA clearance, not De Novo submission.

Why is Ottava at research tier despite J&J's scale?

Per DEPLOY's framework, FDA-clearance-as-gating-event discipline applies symmetrically across corporate scales. Pre-clearance is pre-clearance regardless of company scale; J&J's massive medical-device portfolio does not collapse the verification framework. The framework treats Ottava at the same research tier as Vicarious Surgical V1 (SPAC-era hype period, distressed pre-market) because both lack the verified gating event. Framework discipline applied symmetrically across corporate scales is the editorial differentiator.

What does De Novo mean?

The De Novo pathway is an FDA regulatory pathway for novel medical devices that lack a substantially-equivalent predicate device. The alternative pathway is 510(k), which requires substantial equivalence to a cleared predicate. De Novo submission triggers FDA review; clearance is not automatic and timeline varies materially. Per FDA documented terminology, devices undergoing De Novo review are "not authorized to be marketed" until clearance is granted. The De Novo submission is the regulatory engagement event; FDA clearance is the verified gating event.

How does Ottava compare to da Vinci?

Substantively different verification tiers. Intuitive da Vinci: 11,395 systems installed per SEC 10-Q; da Vinci 5 FDA-cleared March 2024; production tier; gold standard verified deployment across surgical cohort. J&J Ottava: De Novo submission January 2026; FDA records "not authorized to be marketed"; research tier per DEPLOY's framework. Trade-press framings comparing Ottava commercial position to da Vinci dominance should be read against the verification tier differential: production-tier installed base vs pre-market De Novo are structurally different positions in the cohort.

Explainers Surgical robotics

What is Johnson & Johnson Ottava?

Johnson & Johnson Ottava is a surgical robotics platform under development by J&J. Per Agent A foundational ingest, Ottava submitted a De Novo to FDA in January 2026; FDA records list Ottava as 'not authorized to be marketed.' Per DEPLOY's FDA-clearance-as-gating-event framework, Ottava sits at research tier despite J&J's corporate scale. Maturity: research. The pre-market positioning despite J&J's massive medical-device portfolio is the editorial throughline: DEPLOY's framework treats Ottava at the same research tier as Vicarious Surgical V1's distressed pre-market state because both lack the verified gating event. Surfacing this transparently demonstrates the framework discipline applied to household-name corporate scale.

Jan 2026

De Novo FDA submission

Not authorized

Current FDA marketing status

Research

DEPLOY tier per framework

NYSE JNJ

Parent corporate listing

Pre-market

Commercial deployment scope

Mid-2026

Snapshot date

What J&J Ottava is

Johnson & Johnson Ottava is a surgical robotics platform under development by Johnson & Johnson. Per Agent A foundational ingest, Ottava submitted a De Novo to FDA in January 2026; FDA records currently list Ottava as "not authorized to be marketed." Per DEPLOY's FDA-clearance-as-gating-event framework, Ottava sits at research tier despite J&J's corporate scale.

The pre-market positioning is editorially substantial because J&J's corporate scale (a top global medical-device portfolio) does not collapse the verification framework: pre-clearance is pre-clearance regardless of company scale. Per DEPLOY's framework, household-name corporate scale does not substitute for the verified gating event.

Why "research tier" applies despite J&J scale

DEPLOY's verified-vs-claimed framework treats FDA clearance as the gating event for surgical robotics verification. The framework reads:

Cleared platforms (Intuitive da Vinci + Ion; Medtronic Hugo; CMR Versius; Asensus/Karl Storz Senhance; Stereotaxis Genesis; Distalmotion Dexter; Moon Surgical Maestro/ScoPilot; Brain Navi NaoTrac) surface at verification tiers their installed base and clearance scope support.
Pre-market entries (J&J Ottava; Vicarious Surgical V1) read at research tier regardless of corporate-scale or capital-history differences. Both Ottava and Vicarious V1 lack the verified gating event; the framework treats them at the same tier even though J&J is a top-tier global medical-device corporate and Vicarious is a SPAC-era-hype-period distressed pre-market entry.

The framework's discipline is editorially important: it produces consistent verification posture across corporate-scale + emerging entrants. Per DEPLOY's framework, the surgical robotics category needs FDA-clearance-as-gating-event discipline precisely because trade-press coverage often elevates corporate-scale entrants to "near-deployment" framing despite pre-market regulatory status.

The De Novo submission January 2026

Per Agent A foundational ingest, J&J Ottava submitted a De Novo to FDA in January 2026. The De Novo pathway is for novel medical devices that lack a substantially-equivalent predicate device (the alternative pathway is 510(k), which requires substantial equivalence to a cleared predicate). De Novo submission triggers FDA review; clearance is not automatic + timeline varies materially.

FDA records currently list Ottava as "not authorized to be marketed." Per DEPLOY's framework + FDA documented terminology, this is the regulatory state distinguishing pre-clearance from cleared product. Trade-press coverage that frames January 2026 De Novo submission as imminent clearance is editorially imprecise; the verified gating event is FDA clearance, not De Novo submission.

Editorial throughline: corporate scale doesn't equal verified

Per DEPLOY's framework, J&J Ottava is the corporate-scale-doesn't-equal-verified exemplar in DEPLOY's surgical robotics cohort. The framework applies the same FDA-clearance-as-gating-event discipline symmetrically:

J&J Ottava: massive corporate scale; pre-market; research tier per framework.
Vicarious Surgical V1: SPAC-era hype period; distressed pre-market state; research tier per framework.
Both lack the verified gating event; framework treats both at the same tier.

Surfacing this transparently demonstrates the framework discipline applied to a household-name corporate. Per DEPLOY's framework, framework discipline applied symmetrically across corporate scales is the editorial differentiator: framework that softens around household-name corporates is not framework; it is corporate-friendly marketing analysis.

Aggregator-drift caution

Per Agent A's foundational ingest cap-flagging discipline, aggregator coverage has propagated language framing Ottava as a "late-2025 launch" against actual De Novo pre-market status. Per DEPLOY's cap-flag-as-trust-signal, specific Ottava launch + commercial claims should be verified against FDA records + J&J direct communications rather than aggregator-source propagation. The verified state is De Novo submission January 2026 + "not authorized to be marketed"; framings beyond that should be cap-flagged.

Verified-vs-claimed reading

Applying DEPLOY's verified-vs-claimed framework to J&J Ottava:

Company verified: J&J is a real public company (NYSE: JNJ) with a massive medical-device portfolio + multi-decade operating history.
Ottava product verified at research tier: real platform under development; De Novo submission January 2026 confirms regulatory engagement; FDA records confirm pre-market state.
Commercial deployment scope: pre-market. FDA records list as "not authorized to be marketed"; no installed base + no commercial deployment at this state.
Cap-flag on aggregator launch claims: per Agent A ingest discipline, aggregator framings of "late-2025 launch" or imminent commercial deployment should be verified against FDA records + J&J direct communications; the verified state is De Novo + pre-market.

Where Ottava fits in the cohort

Per DEPLOY's surgical robotics framework, Ottava sits at the pre-market research tier alongside Vicarious Surgical V1. Other cohort positions:

Production scale: Intuitive da Vinci + Ion at 11,395 + 1,041 installed per SEC 10-Q.
Cleared commercial: Medtronic Hugo, CMR Versius, Senhance, Genesis, Dexter, Moon Maestro/ScoPilot (FDA-cleared with PCCP), Brain Navi NaoTrac (autonomous registration).
Pre-market research: J&J Ottava (De Novo January 2026); Vicarious Surgical V1 (SPAC-era hype, distressed pre-market).

The cohort-positioning differential is editorially substantial: pre-market research tier carries distinct verification questions than cleared-commercial tier. For Ottava specifically, the operator question is whether De Novo review produces clearance + commercial deployment outcomes that the framework will surface at cleared-commercial tier; the framework cap-flags forward state pending the regulatory gating event.

Where to go for context

For broader surgical robotics cohort context + cohort enumeration + cohort autonomy spectrum + FDA-clearance-as-gating-event framework, see what is a surgical robot. For the verified-at-scale anchor of the surgical cohort, see what is Intuitive Surgical da Vinci. For broader physical AI category context, see what is physical AI.

For the canonical J&J record (corporate scale, medical-device portfolio, financial state), see Johnson & Johnson's registry entity. For the framework DEPLOY applies to verifying capability and deployment claims across operators, see how DEPLOY verifies capability claims. For methodology canonical references applicable to J&J Ottava: the 4-way autonomy-boundary taxonomy (replacement-robotics pre-market tier; De Novo submission January 2026) + the 9-tier source-quality rubric (FDA De Novo + J&J SEC corporate-scale source classification).

Source: FDA records + DEPLOY registry + per-entity operational records + Agent A foundational ingest. FDA-clearance-as-gating-event + symmetric-discipline framework.
Entity	Clearance posture	Corporate / capital context	Tier
J&J Ottava	De Novo January 2026; not authorized to be marketed	Massive corporate scale (NYSE: JNJ)	Research
Vicarious Surgical V1	Pre-clearance	SPAC-era hype period; distressed pre-market state	Research
Intuitive da Vinci	Cleared (da Vinci 5 March 2024)	NASDAQ ISRG; 11,395 installed	Production
Moon Surgical Maestro (ScoPilot)	Cleared with PCCP	Genuine shipped surgical AI standout	Commercial
Medtronic Hugo	Cleared by indication + geography	Corporate-scale entrant; cleared progression	Commercial
Brain Navi NaoTrac	Cleared (autonomous registration)	Narrow autonomous function in selected geographies	Commercial

Frequently asked questions

What is J&J Ottava?: Johnson & Johnson Ottava is a surgical robotics platform under development by Johnson & Johnson (NYSE: JNJ). Per Agent A foundational ingest, Ottava submitted a De Novo to FDA in January 2026; FDA records list Ottava as "not authorized to be marketed." Per DEPLOY's FDA-clearance-as-gating-event framework, Ottava sits at research tier despite J&J's corporate scale.
Is J&J Ottava FDA cleared?: No. Per FDA records + Agent A foundational ingest, Ottava has NOT yet received FDA clearance. The verified state is De Novo submission January 2026; FDA records list Ottava as "not authorized to be marketed." The De Novo pathway is for novel medical devices lacking a substantially-equivalent predicate; clearance is not automatic + timeline varies materially. Trade-press coverage framing January 2026 De Novo submission as imminent clearance is editorially imprecise; the verified gating event is FDA clearance, not De Novo submission.
Why is Ottava at research tier despite J&J's scale?: Per DEPLOY's framework, FDA-clearance-as-gating-event discipline applies symmetrically across corporate scales. Pre-clearance is pre-clearance regardless of company scale; J&J's massive medical-device portfolio does not collapse the verification framework. The framework treats Ottava at the same research tier as Vicarious Surgical V1 (SPAC-era hype period, distressed pre-market) because both lack the verified gating event. Framework discipline applied symmetrically across corporate scales is the editorial differentiator.
What does De Novo mean?: The De Novo pathway is an FDA regulatory pathway for novel medical devices that lack a substantially-equivalent predicate device. The alternative pathway is 510(k), which requires substantial equivalence to a cleared predicate. De Novo submission triggers FDA review; clearance is not automatic and timeline varies materially. Per FDA documented terminology, devices undergoing De Novo review are "not authorized to be marketed" until clearance is granted. The De Novo submission is the regulatory engagement event; FDA clearance is the verified gating event.
When will J&J Ottava launch commercially?: Unknown. Per FDA records + Agent A foundational ingest, the verified state is De Novo submission January 2026 + "not authorized to be marketed." Per DEPLOY's cap-flag-as-trust-signal, specific commercial-launch timing claims should be verified against FDA records + J&J direct communications rather than aggregator-source propagation. Aggregator coverage propagating "late-2025 launch" framings against actual De Novo pre-market status is the specific aggregator drift Agent A foundational ingest cap-flagged.
How does Ottava compare to da Vinci?: Substantively different verification tiers. Intuitive da Vinci: 11,395 systems installed per SEC 10-Q; da Vinci 5 FDA-cleared March 2024; production tier; gold standard verified deployment across surgical cohort. J&J Ottava: De Novo submission January 2026; FDA records "not authorized to be marketed"; research tier per DEPLOY's framework. Trade-press framings comparing Ottava commercial position to da Vinci dominance should be read against the verification tier differential: production-tier installed base vs pre-market De Novo are structurally different positions in the cohort.

J&J Ottava verified at research tier: De Novo FDA submission January 2026 + FDA records 'not authorized to be marketed.' Per DEPLOY's FDA-clearance-as-gating-event framework, Ottava sits at the same research tier as Vicarious Surgical V1 despite distinct corporate-scale + capital histories; both lack the verified gating event. Corporate-scale-doesn't-equal-verified exemplar across the surgical cohort. How DEPLOY verifies →

Compare alternatives

Johnson & Johnson registry entityJ&J Ottava pricing pageWhat is a surgical robot?Intuitive Surgical da Vinci explainerVicarious Surgical registry entity

Defined terms in this explainer

Deployment

More in surgical robotics

View all 18 explainers in surgical robotics →

← All explainers